If they needed to do a secondary they would do it already. They'll have enough $$$ to get to the end of next year with the cash that they have now. If they need cash, they'll do a partnership or wait until the pancreatic cancer data comes out. The share price is way too low for a secondary to be a reasonable option with the better options on the table.
Sentiment: Strong Buy